Bergman, Correa Applaud New FDA Guidance to Help Those Suffering from PTSD

Today, Representative Jack Bergman (MI-01) and Representative Lou Correa (CA-46), co-chairs of the Psychedelics Advancing Therapies (PATH) Caucus, released the following statement:

"We applaud the Food and Drug Administration (FDA) for their considerable work in releasing the non-binding guidance for comment regarding the clinical study and development of psychedelic therapies for those suffering from mental and behavioral health conditions. Notably, within the last five years, the FDA awarded its coveted Breakthrough Therapy Designation to multiple psychedelic therapies including MDMA for PTSD and psilocybin for treatment-resistant depression and major depressive disorder. As our country continues to suffer tragic rates of suicide and opioid overdose deaths, which disproportionately impact our Nation’s military Veterans, it is critical that policymakers such as those in our caucus pursue additional pragmatic measures – alongside the relevant agencies – to ensure that those who would benefit most from these potentially lifesaving therapies can get access as soon as possible."

Stay Connected

Use the form below to sign up for my newsletter and get the latest news and updates directly to your inbox.